CMI Strategic Funding Opportunities
Total amount available for this initiative is $13.275 million, with the possibility of increased funding through additional partnerships.
Letters of Intent are due November 2, 2009 and funding will commence in September 2010.
This funding opportunity is supported by:
- The CIHR Institute of Infection and Immunity in partnership with:
- The CIHR Institute of Cancer Research,
- The CIHR Institute of Musculoskeletal Health and Arthritis,
- The CIHR Institute of Nutrition, Metabolism and Diabetes,
- The CIHR Ethics Office,
- The Canadian Cystic Fibrosis Foundation,
- The Crohn's and Colitis Foundation of Canada,
- Genome British Columbia,
- Genome Prairie,
- Institut Rosell - Lallemand Inc.
- The Canadian Healthy Infant Longitudinal Development (CHILD) Study,
- The Canadian Longitudinal Study on Aging (CLSA),
- The Canadian Partnership for Tomorrow Project (CPT),
- the International Human Microbiome Consortium (IHMC)
The specific objectives of this funding opportunity are:
- To characterize communities of microbes found in different body sites in healthy individuals to determine if individuals share a common microbiome;
- To explore the interactions between microbes and determine how perturbations at one site can affect microbes at another body site;
- To investigate the role the microbiota play in human health and to probe the associations between the human microbiome and a variety of diseases and health conditions;
- To establish links and collaborations between researchers with expertise in different fields e.g. genomics, proteomics, bioinformatics, immunology, physiology, microbial ecology, ethics;
- To establish links and collaborations between research teams currently studying microbes at different body sites e.g. oral, gastrointestinal, respiratory tract;
- To promote research that utilizes existing Canadian infrastructures such as large-scale genomics and bioinformatics platforms and cohort studies;
- To create competitive Canadian teams that are able to contribute to, and benefit from, the work of the IHMC and other international opportunities;
- To identify and address potential ethical and legal issues associated with microbiome research and the emerging technologies as an integral part of research teams.
|Allen-Vercoe, Emma||University of Guelph||Investigating the potential effects of host-derived stress hormones on the human gut microflora|
|Finlay, Barton||University of British Columbia||The Role of the Gastrointestinal Microbiota in Asthma|
|Holt, Rob||BC Cancer Research Centre||Linking Infectious Agents to Cancer: A Metagenomics Approach|
|Hwang, David||University Health Network||Assessing the impact of polymicrobial pulmonary infections in cystic fibrosis via metagenomics|
|Kozyrskyj, Anita||University of Alberta||The impact of antibiotics on intestinal microbiota of infants|
|Manges, Amee||McGill University||Microbial metagenomics of the intestinal microbiota and the etiology of Clostridium difficile-associated disease in hospitalized patients|
|Money, Deborah||University of British Columbia||Metagenomic characterization of the human vaginal microbiome|
|Neufeld, Josh||University of Waterloo||Establishing a complete taxonomic baseline for the human microbiome|
|O'Doherty, Kieran||University of British Columbia||Developing Ethical and Regulatory Guidelines for Research on the Human Microbiome and its Applications: Speaking to the Experts and Stakeholders|
|Rioux, Kevin||University of Calgary||Characterizing the fecal microbiome and bacteria-derived volatile organic compounds in patients with non-alcoholic fatty liver disease (NAFLD)|
|Stintzi, Alain||University of Ottawa||Role of the gut microbiome in Pediatric Gastrointestinal Illnesses|
|Surette, Michael||University of Calgary||Elusive respiratory pathogens in the oropharyngeal flora|
For more details see the Overview of the Canadian Microbiome Initiative.
Supplemental content (right column)